3rd Circ.: Biotech Must Pay Royalties Despite Expired Patents
By Hannah Albarazi · September 3, 2024, 7:00 PM EDT
A cancer drug biotechnology company must pay royalties to a research firm despite the expiration of the applicable patents, a Third Circuit panel ruled in a precedential decision Tuesday, concluding that...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login